ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
LONDON--(BUSINESS WIRE)--For media and investors only ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (「GSK」), with Pfizer Inc. and Shionogi Limited ......
